We compared the effectiveness of rifampin-trimethoprim in fixed combination (3.75:1) 
We compared the effectiveness of rifampin-trimethoprim in fixed combination (3.75:1) The high secondary attack rate documented among contacts (5) of patients with invasive
Haemophilus influenzae type b (Hib) disease has stimulated efforts to identify an antibiotic regimen which might interrupt transmission of Hib among those at risk. To date, the most promising chemoprophylactic agent has been rifampin. However, the isolation of H. influenzae strains resistant to this agent (10, 11) has raised concern that its effectiveness might be compromised by widespread use. Recently, in vitro synergy has been demonstrated for trimethoprim and rifampin in combination against H. influenzae (1, 7). In addition, the use of two antimicrobial agents together might diminish the likelihood of isolating resistant mutants (12 The MIC was defined as the lowest concentration of antibiotic which inhibited growth. Minimal bactericidal concentrations (MBCs) were determined by subculturing from the microdilution plates with a 10-a,l Eppendorf pipette (Brinkmann Instruments, Inc., Westbury, N.Y.). Samples from each clear well were plated on brain heart infusion agar supplemented with hemin (final concentration, 1 mg/ml) and ,B-NAD (final concentration, 1 ,ug/ml) and incubated overnight. Thus, the MBC was defined as the lowest antibiotic concentration from which no viable organisms could be recovered (>99.9o kill). Isolates tested included the pre-and posttreatment isolates from 40 of 42 contacts who remained colonized with Hib after prophylaxis.
The X2 test was used to compare the carriage eradication rates of the rifampin and rifampin-trimethoprim groups. A log linear model was used to test for the distribution of Hib carriage by age and for the infectious syndrome of the index patient. The X2 test was used to compare the incidence of side effects between the drug groups. A paired t test was used to compare the MICs and MBCs of the drugs for pre-and posttreatment Hib isolates in contacts who remained colonized after prophylaxis.
RESULTS
Index patients and patient contact groups. During the study period, 127 index patients (New Orleans, 43; Denver, 45; Boston, 39) were hospitalized during the study period. At the initial interview, 620 household contacts were identified. The mean age of the index patients was 17.4 months. Of the 127 index patients, 71% had meningitis, 8% had epiglottitis, and 21% had other Hib syndromes; 58% were male; and 15% attended a day-care center.
A PCG contained a mean of 5.1 individuals. Of the PCGs, 63% included at least one individual <5 years of age, in addition to the index case.
Carriage among contacts. Of 620 patient contacts, 161 (26.0%) were initially colonized with Hib. The distribution of colonized contacts by age resembled that observed previously (4) . Hib colonization in children s9 years of age was documented in 116 of 220 individuals (52.7%), whereas 45 of 400 individuals (11.3%) >9 years were colonized (P < 0.0001; X2). In contacts <5 years of age, the carriage rate varied significantly (P < .05) with the infectious syndrome of the index case: in contacts <5 years of age, 62% were colonized when the index patient had meningitis, 18% were colonized when the infectious syndrome of the index patient was epiglottitis, and 32% were colonized when the index patient had other Hib syndromes.
Follow-up and compliance. Of the 620 PCG members, 559 (90.1%) returned 10 days after the initial visit for follow-up culture. A study drug was not prescribed for nine of these individuals who were pregnant. Of the 550 members who returned and were eligible for prophylaxis, 524 (95.3%) reported full compliance with the prescribed regimen.
Eradication and acquisition of Hib carriage. Of the 161 contact-carriers identified initially, 152 (94.4%) returned 10 days later for follow-up. Eight of these individuals were excluded from the calculation of eradication rates; rifampin was contraindicated in one, and seven took three or fewer doses of rifampin. Thus, 144 contactcarriers reported full compliance and returned for follow-up. We also studied 15 compliant carriers who had requested inclusion in the study despite insufficient contact with the index patient to qualify as an authentic PCG member. A prophylactic regimen identical to that of the bona fide PCG members was prescribed for these individuals. Data regarding carriage eradication in the 159 carriers are shown in Table 1 . The rate of acquisition of Hib carriage between the time of the initial culture and the follow-up visit 10 days later did not differ significantly when all contacts (2.4% rifampin versus 2.5% rifampin-trimethoprim), contacts -5 years of age (0.7% rifampin versus 0.6% rifampin-trimethoprim), and contacts <5 years of age (12.0% rifampin versus 12.5% rifampin-trimethoprim) were compared.
Toxicity. The incidence of side effects reported by contacts receiving rifampin was compared with that reported by rifampin-trimethoprim re- 1.88 ,ug/ml); after therapy, the mean MIC was 0.39 ,ug/ml (range, 0.06 to 1.88 pg/ml). For rifampin-trimethoprim, the pretreatment mean MIC averaged 0.33-0.09 pLg/ml (range, 0.06-0.02 to 0.94-0.25 ,ug/ml), whereas the mean MIC after therapy was 0.35-0.09 ,g/ml (range, 0.03-0.01 to 0.94-0.25 ,g/ml). The MICs of rifampin and rifampin-trimethoprim for isolates of patients who remained colonized after prophylaxis did not differ with the prescribed regimen. In 37 of 40 strains tested, the MIC and MBC of rifampin-trimethoprim were identical. In three strains, the MBC (0.94-0.25 ,ug/ml) exceeded the MIC (0.12-0.04 ,ug/ml) by three dilutions. Synergy at a ratio of rifampin to trimethoprim of 3.75:1 could not be inferred since the MIC of rifampin when tested in combination with trimethoprim was never more than a single dilution lower than the MIC of rifampin when tested alone.
One isolate of H. influenzae resistant to rifampin was encountered in an individual who did not satisfy the contact criteria but who took rifampin after isolation of Hib from the pharynx. Before treatment the MIC and MBC of rifampin had been 0.47 ,ug/ml, whereas the MIC and MBC of rifampin-trimethoprim were 0.23-0.07 and 0.47-0.13 ,ug/ml, respectively. This individual ANTIMICROB. AGENTS CHEMOTHER. remained a carrier after rifampin therapy and then was treated with rifampin-trimethoprim. However, Hib was again isolated from the oropharynx 10 days after therapy. The MIC and MBC of rifampin for this isolate were both 3.75 ,ug/ml, whereas the MIC and MBC of rifampintrimethoprim were 1.88-0.5 and 7.5-2 >g/ml, respectively.
DISCUSSION
We previously reported our experience with rifampin at the dose and regimen currently recommended for household contacts of patients with serious meningococcal infections (20 mg/kg per day twice daily for 2 days; maximum dose 1,200 mg per day) (6) . Overall, rifampin eradicated carriage more effectively than did placebo in household contacts. However, in children <5 years of age, the rifampin eradication rate (47.8%) did not significantly exceed that observed with placebo (28.6%).
The combination of rifampin-trimethoprim was not significantly better than rifampin alone among all household contacts ( influenzae. Mutation to rifampin resistance occurs readily in vitro (8, 12) . Moreover, failure of rifampin prophylaxis has been associated with isolation of resistant strains of H. influenzae (10, 11) . Importantly, the in vitro emergence of rifampin-resistant mutants was prevented when trimethoprim was combined with rifampin (12) .
In our study, rifampin and subsequent rifampin-trimethoprim prophylaxis failed in an individual in association with isolation of an Hib strain resistant to rifampin. The explanation for failure of eradication in the 41 other individuals who remained colonized after therapy is not known. Problems in during administration were encountered very rarely. With the exception of transient discoloration of urine and menstruallike bleeding reported by an occasional rifampin recipient taking birth control pills, little toxicity was encountered.
Our data confirm that the 2-day rifampin regimen we employed does not dependably eradicate carriage in children <5 years of age. In addition, administration of rifampin-trimethoprim for 2 days failed to eradicate carriage in 28.9o of children <5 years of age. It is possible that in some failures, the organism was successfully eradicated but the carrier was recolonized during the 10-day study period. Since the goal of prophylaxis is dependable elimination of the reservoir of Hib carriage surrounding the index patient, the failure rate we observed is unacceptably high. Whether a regimen that dependably eradicates the carrier state may be presumed to also reduce secondary invasive disease remains unknown. Nevertheless, if the currently recommended (2, 3) regimen of rifampin in a dose of 20 mg/kg (maximum dose, 600 mg) once daily for 4 days is associated with frequent isolation of resistant strains, rifampin-trimethoprim at a higher dosage or for a longer period of time might merit clinical trial.
